このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
Aurinia Pharmaceuticals 過去の業績
過去 基準チェック /06
Aurinia Pharmaceuticalsの収益は年間平均-2.3%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.5% 57.6%割合で 増加しています。
主要情報
-2.3%
収益成長率
6.2%
EPS成長率
Biotechs 業界の成長 | 17.0% |
収益成長率 | 57.6% |
株主資本利益率 | -17.4% |
ネット・マージン | -32.7% |
前回の決算情報 | 31 Mar 2024 |
最近の業績更新
Recent updates
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
May 24Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
May 05Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
May 02Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus
Sep 19Aurinia Pharmaceuticals: The Right Play Now
Aug 24Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model
Aug 15Aurinia Pharma Q2 2022 Earnings Preview
Aug 03Aurinia lupus nephritis drug recommended in Europe
Jul 22A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)
Jul 04収支内訳
収支内訳
Aurinia Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
31 Mar 24 | 191 | -63 | 193 | 0 |
31 Dec 23 | 176 | -78 | 195 | 0 |
30 Sep 23 | 159 | -77 | 192 | 0 |
30 Jun 23 | 160 | -73 | 197 | 0 |
31 Mar 23 | 147 | -97 | 201 | 0 |
31 Dec 22 | 134 | -108 | 196 | 0 |
30 Sep 22 | 129 | -115 | 194 | 0 |
30 Jun 22 | 88 | -157 | 186 | 0 |
31 Mar 22 | 66 | -168 | 179 | 0 |
31 Dec 21 | 46 | -181 | 174 | 0 |
30 Sep 21 | 72 | -156 | 168 | 0 |
30 Jun 21 | 58 | -148 | 154 | 0 |
31 Mar 21 | 51 | -127 | 125 | 0 |
31 Dec 20 | 50 | -103 | 97 | 0 |
30 Sep 20 | 0 | -129 | 64 | 0 |
30 Jun 20 | 0 | -110 | 40 | 0 |
31 Mar 20 | 0 | -102 | 29 | 0 |
31 Dec 19 | 0 | -88 | 22 | 0 |
30 Sep 19 | 0 | -57 | 19 | 0 |
30 Jun 19 | 0 | -52 | 15 | 0 |
31 Mar 19 | 0 | -61 | 14 | 0 |
31 Dec 18 | 0 | -53 | 14 | 0 |
30 Sep 18 | 0 | -53 | 14 | 0 |
30 Jun 18 | 0 | -48 | 14 | 0 |
31 Mar 18 | 0 | -34 | 13 | 0 |
31 Dec 17 | 0 | -71 | 12 | 0 |
30 Sep 17 | 0 | -76 | 11 | 0 |
30 Jun 17 | 0 | -70 | 10 | 0 |
31 Mar 17 | 0 | -71 | 9 | 0 |
31 Dec 16 | 0 | -23 | 7 | 0 |
30 Sep 16 | 0 | -19 | 6 | 0 |
30 Jun 16 | 0 | -17 | 6 | 0 |
31 Mar 16 | 0 | -14 | 6 | 0 |
31 Dec 15 | 0 | -19 | 6 | 0 |
30 Sep 15 | 0 | -21 | 6 | 0 |
30 Jun 15 | 0 | -13 | 6 | 0 |
31 Mar 15 | 0 | -23 | 6 | 0 |
31 Dec 14 | 0 | -19 | 7 | 0 |
30 Sep 14 | 1 | -15 | 6 | 0 |
30 Jun 14 | 1 | -17 | 5 | 0 |
31 Mar 14 | 1 | -7 | 4 | 0 |
31 Dec 13 | 1 | -3 | 2 | 0 |
30 Sep 13 | 0 | -6 | 2 | 0 |
質の高い収益: AUPHは現在利益が出ていません。
利益率の向上: AUPHは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: AUPHは利益が出ておらず、過去 5 年間で損失は年間2.3%の割合で増加しています。
成長の加速: AUPHの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: AUPHは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。
株主資本利益率
高いROE: AUPHは現在利益が出ていないため、自己資本利益率 ( -17.4% ) はマイナスです。